These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35845260)

  • 1. Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology.
    Berry K; Asken BM; Grab JD; Chan B; Lario Lago A; Wong R; Seetharaman S; LaHue SC; Possin KL; Rojas JC; Kramer JH; Boxer AL; Lai JC; VandeVrede L
    Alzheimers Dement (Amst); 2022; 14(1):e12321. PubMed ID: 35845260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma biomarker profiles in autosomal dominant Alzheimer's disease.
    Johansson C; Thordardottir S; Laffita-Mesa J; Rodriguez-Vieitez E; Zetterberg H; Blennow K; Graff C
    Brain; 2023 Mar; 146(3):1132-1140. PubMed ID: 36626935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
    Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease marker phospho-tau181 is not elevated in the first year after moderate-to-severe TBI.
    Graham N; Zimmerman K; Heslegrave AJ; Keshavan A; Moro F; Abed-Maillard S; Bernini A; Dunet V; Garbero E; Nattino G; Chieregato A; Fainardi E; Baciu C; Gradisek P; Magnoni S; Oddo M; Bertolini G; Schott JM; Zetterberg H; Sharp D
    J Neurol Neurosurg Psychiatry; 2024 Mar; 95(4):356-359. PubMed ID: 37833041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
    Frontera JA; Boutajangout A; Masurkar AV; Betensky RA; Ge Y; Vedvyas A; Debure L; Moreira A; Lewis A; Huang J; Thawani S; Balcer L; Galetta S; Wisniewski T
    Alzheimers Dement; 2022 May; 18(5):899-910. PubMed ID: 35023610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
    Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M
    Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Markers of Neurodegeneration Are Raised in Friedreich's Ataxia.
    Zeitlberger AM; Thomas-Black G; Garcia-Moreno H; Foiani M; Heslegrave AJ; Zetterberg H; Giunti P
    Front Cell Neurosci; 2018; 12():366. PubMed ID: 30425621
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma UCHL1, GFAP, Tau, and NfL Are Not Different in Young Healthy Persons With Mild COVID-19 Symptoms Early in the Pandemic: A Pilot Study.
    Rogatzki MJ; Szeghy RE; Stute NL; Province VM; Augenreich MA; Stickford JL; Stickford ASL; Hanson ED; Ratchford SM
    Neurotrauma Rep; 2023; 4(1):330-341. PubMed ID: 37284701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma tau, NfL, GFAP and UCHL1 as candidate biomarkers of alcohol withdrawal-associated brain damage: A pilot study.
    Clergue-Duval V; Vrillon A; Jeanblanc J; Questel F; Azuar J; Fouquet G; Mouton-Liger F; Rollet D; Hispard E; Bouaziz-Amar E; Bloch V; Dereux A; Cognat E; Marie-Claire C; Laplanche JL; Bellivier F; Paquet C; Naassila M; Vorspan F
    Addict Biol; 2022 Nov; 27(6):e13232. PubMed ID: 36301211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia.
    Thijssen EH; Verberk IMW; Kindermans J; Abramian A; Vanbrabant J; Ball AJ; Pijnenburg Y; Lemstra AW; van der Flier WM; Stoops E; Hirtz C; Teunissen CE
    Alzheimers Dement (Amst); 2022; 14(1):e12285. PubMed ID: 35603139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia.
    Silva-Spínola A; Lima M; Leitão MJ; Bernardes C; Durães J; Duro D; Tábuas-Pereira M; Santana I; Baldeiras I
    Eur J Neurol; 2023 Jun; 30(6):1565-1573. PubMed ID: 36880887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
    Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
    Huang Y; Li Y; Xie F; Guo Q
    CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
    Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
    Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
    Chen CH; Cheng YW; Chen YF; Tang SC; Jeng JS
    J Neuroinflammation; 2020 Apr; 17(1):124. PubMed ID: 32321529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.